Antiobesity action of peripheral exenatide (exendin-4) in rodents: Effects on food intake, body weight, metabolic status and side-effect measures

C. M. Mack, C. X. Moore, C. M. Jodka, S. Bhavsar, J. K. Wilson, J. A. Hoyt, J. L. Roan, C. Vu, K. D. Laugero, D. G. Parkes, A. A. Young

Research output: Contribution to journalArticle

100 Citations (Scopus)

Abstract

Background:Exenatide (exendin-4) is an incretin mimetic currently marketed as an antidiabetic agent for patients with type 2 diabetes. In preclinical models, a reduction in body weight has also been shown in low-fat-fed, leptin receptor-deficient rodents.Objective:To more closely model the polygenic and environmental state of human obesity, we characterized the effect of exenatide on food intake and body weight in high-fat-fed, normal (those with an intact leptin signaling system) rodents. As glucagon-like peptide-1 receptor agonism has been found to elicit behaviors associated with visceral illness in rodents, we also examined the effect of peripheral exenatide on kaolin consumption and locomotor activity.Methods and results:High-fat-fed C57BL/6 mice and Sprague-Dawley rats were treated with exenatide (3, 10 and 30 μg/kg/day) for 4 weeks via subcutaneously implanted osmotic pumps. Food intake and body weight were assessed weekly. At 4 weeks, body composition and plasma metabolic profiles were measured. Kaolin consumption and locomotor activity were measured in fasted Sprague-Dawley rats following a single intraperitoneal injection of exenatide (0.1-10 μg/kg). Exenatide treatment in mice and rats dose-dependently decreased food intake and body weight; significant reductions in body weight gain were observed throughout treatment at 10 and 30 μg/kg/day (P<0.05). Decreased body weight gain was associated with a significant decrease in fat mass (P<0.05) with sparing of lean tissue. Plasma cholesterol, triglycerides and insulin were also significantly reduced (P<0.05). Exenatide at 10 μg/kg significantly reduced food intake (P<0.05) but failed to induce kaolin intake. In general, locomotor activity was reduced at doses of exenatide that decreased food intake, although a slightly higher dose was required to produce significant changes in activity.Conclusion:Systemic exenatide reduces body weight gain in normal, high-fat-fed rodents, a model that parallels human genetic variation and food consumption patterns, and may play a role in metabolic pathways mediating food intake.

Original languageEnglish (US)
Pages (from-to)1332-1340
Number of pages9
JournalInternational Journal of Obesity
Volume30
Issue number9
DOIs
StatePublished - Sep 21 2006
Externally publishedYes

Fingerprint

food intake
Rodentia
rodents
Eating
adverse effects
Body Weight
body weight
kaolin
Kaolin
locomotion
Fats
lipids
weight gain
Locomotion
Weight Gain
rats
dosage
hypoglycemic agents
secretin
Sprague Dawley Rats

Keywords

  • Body composition
  • High fat diet
  • Kaolin consumption
  • Locomotor activity
  • Metabolites
  • Type 2 diabetes

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Public Health, Environmental and Occupational Health
  • Endocrinology
  • Food Science
  • Endocrinology, Diabetes and Metabolism

Cite this

Antiobesity action of peripheral exenatide (exendin-4) in rodents : Effects on food intake, body weight, metabolic status and side-effect measures. / Mack, C. M.; Moore, C. X.; Jodka, C. M.; Bhavsar, S.; Wilson, J. K.; Hoyt, J. A.; Roan, J. L.; Vu, C.; Laugero, K. D.; Parkes, D. G.; Young, A. A.

In: International Journal of Obesity, Vol. 30, No. 9, 21.09.2006, p. 1332-1340.

Research output: Contribution to journalArticle

Mack, CM, Moore, CX, Jodka, CM, Bhavsar, S, Wilson, JK, Hoyt, JA, Roan, JL, Vu, C, Laugero, KD, Parkes, DG & Young, AA 2006, 'Antiobesity action of peripheral exenatide (exendin-4) in rodents: Effects on food intake, body weight, metabolic status and side-effect measures', International Journal of Obesity, vol. 30, no. 9, pp. 1332-1340. https://doi.org/10.1038/sj.ijo.0803284
Mack, C. M. ; Moore, C. X. ; Jodka, C. M. ; Bhavsar, S. ; Wilson, J. K. ; Hoyt, J. A. ; Roan, J. L. ; Vu, C. ; Laugero, K. D. ; Parkes, D. G. ; Young, A. A. / Antiobesity action of peripheral exenatide (exendin-4) in rodents : Effects on food intake, body weight, metabolic status and side-effect measures. In: International Journal of Obesity. 2006 ; Vol. 30, No. 9. pp. 1332-1340.
@article{be848740571d4c719930a921dc75d8f2,
title = "Antiobesity action of peripheral exenatide (exendin-4) in rodents: Effects on food intake, body weight, metabolic status and side-effect measures",
abstract = "Background:Exenatide (exendin-4) is an incretin mimetic currently marketed as an antidiabetic agent for patients with type 2 diabetes. In preclinical models, a reduction in body weight has also been shown in low-fat-fed, leptin receptor-deficient rodents.Objective:To more closely model the polygenic and environmental state of human obesity, we characterized the effect of exenatide on food intake and body weight in high-fat-fed, normal (those with an intact leptin signaling system) rodents. As glucagon-like peptide-1 receptor agonism has been found to elicit behaviors associated with visceral illness in rodents, we also examined the effect of peripheral exenatide on kaolin consumption and locomotor activity.Methods and results:High-fat-fed C57BL/6 mice and Sprague-Dawley rats were treated with exenatide (3, 10 and 30 μg/kg/day) for 4 weeks via subcutaneously implanted osmotic pumps. Food intake and body weight were assessed weekly. At 4 weeks, body composition and plasma metabolic profiles were measured. Kaolin consumption and locomotor activity were measured in fasted Sprague-Dawley rats following a single intraperitoneal injection of exenatide (0.1-10 μg/kg). Exenatide treatment in mice and rats dose-dependently decreased food intake and body weight; significant reductions in body weight gain were observed throughout treatment at 10 and 30 μg/kg/day (P<0.05). Decreased body weight gain was associated with a significant decrease in fat mass (P<0.05) with sparing of lean tissue. Plasma cholesterol, triglycerides and insulin were also significantly reduced (P<0.05). Exenatide at 10 μg/kg significantly reduced food intake (P<0.05) but failed to induce kaolin intake. In general, locomotor activity was reduced at doses of exenatide that decreased food intake, although a slightly higher dose was required to produce significant changes in activity.Conclusion:Systemic exenatide reduces body weight gain in normal, high-fat-fed rodents, a model that parallels human genetic variation and food consumption patterns, and may play a role in metabolic pathways mediating food intake.",
keywords = "Body composition, High fat diet, Kaolin consumption, Locomotor activity, Metabolites, Type 2 diabetes",
author = "Mack, {C. M.} and Moore, {C. X.} and Jodka, {C. M.} and S. Bhavsar and Wilson, {J. K.} and Hoyt, {J. A.} and Roan, {J. L.} and C. Vu and Laugero, {K. D.} and Parkes, {D. G.} and Young, {A. A.}",
year = "2006",
month = "9",
day = "21",
doi = "10.1038/sj.ijo.0803284",
language = "English (US)",
volume = "30",
pages = "1332--1340",
journal = "International Journal of Obesity",
issn = "0307-0565",
publisher = "Nature Publishing Group",
number = "9",

}

TY - JOUR

T1 - Antiobesity action of peripheral exenatide (exendin-4) in rodents

T2 - Effects on food intake, body weight, metabolic status and side-effect measures

AU - Mack, C. M.

AU - Moore, C. X.

AU - Jodka, C. M.

AU - Bhavsar, S.

AU - Wilson, J. K.

AU - Hoyt, J. A.

AU - Roan, J. L.

AU - Vu, C.

AU - Laugero, K. D.

AU - Parkes, D. G.

AU - Young, A. A.

PY - 2006/9/21

Y1 - 2006/9/21

N2 - Background:Exenatide (exendin-4) is an incretin mimetic currently marketed as an antidiabetic agent for patients with type 2 diabetes. In preclinical models, a reduction in body weight has also been shown in low-fat-fed, leptin receptor-deficient rodents.Objective:To more closely model the polygenic and environmental state of human obesity, we characterized the effect of exenatide on food intake and body weight in high-fat-fed, normal (those with an intact leptin signaling system) rodents. As glucagon-like peptide-1 receptor agonism has been found to elicit behaviors associated with visceral illness in rodents, we also examined the effect of peripheral exenatide on kaolin consumption and locomotor activity.Methods and results:High-fat-fed C57BL/6 mice and Sprague-Dawley rats were treated with exenatide (3, 10 and 30 μg/kg/day) for 4 weeks via subcutaneously implanted osmotic pumps. Food intake and body weight were assessed weekly. At 4 weeks, body composition and plasma metabolic profiles were measured. Kaolin consumption and locomotor activity were measured in fasted Sprague-Dawley rats following a single intraperitoneal injection of exenatide (0.1-10 μg/kg). Exenatide treatment in mice and rats dose-dependently decreased food intake and body weight; significant reductions in body weight gain were observed throughout treatment at 10 and 30 μg/kg/day (P<0.05). Decreased body weight gain was associated with a significant decrease in fat mass (P<0.05) with sparing of lean tissue. Plasma cholesterol, triglycerides and insulin were also significantly reduced (P<0.05). Exenatide at 10 μg/kg significantly reduced food intake (P<0.05) but failed to induce kaolin intake. In general, locomotor activity was reduced at doses of exenatide that decreased food intake, although a slightly higher dose was required to produce significant changes in activity.Conclusion:Systemic exenatide reduces body weight gain in normal, high-fat-fed rodents, a model that parallels human genetic variation and food consumption patterns, and may play a role in metabolic pathways mediating food intake.

AB - Background:Exenatide (exendin-4) is an incretin mimetic currently marketed as an antidiabetic agent for patients with type 2 diabetes. In preclinical models, a reduction in body weight has also been shown in low-fat-fed, leptin receptor-deficient rodents.Objective:To more closely model the polygenic and environmental state of human obesity, we characterized the effect of exenatide on food intake and body weight in high-fat-fed, normal (those with an intact leptin signaling system) rodents. As glucagon-like peptide-1 receptor agonism has been found to elicit behaviors associated with visceral illness in rodents, we also examined the effect of peripheral exenatide on kaolin consumption and locomotor activity.Methods and results:High-fat-fed C57BL/6 mice and Sprague-Dawley rats were treated with exenatide (3, 10 and 30 μg/kg/day) for 4 weeks via subcutaneously implanted osmotic pumps. Food intake and body weight were assessed weekly. At 4 weeks, body composition and plasma metabolic profiles were measured. Kaolin consumption and locomotor activity were measured in fasted Sprague-Dawley rats following a single intraperitoneal injection of exenatide (0.1-10 μg/kg). Exenatide treatment in mice and rats dose-dependently decreased food intake and body weight; significant reductions in body weight gain were observed throughout treatment at 10 and 30 μg/kg/day (P<0.05). Decreased body weight gain was associated with a significant decrease in fat mass (P<0.05) with sparing of lean tissue. Plasma cholesterol, triglycerides and insulin were also significantly reduced (P<0.05). Exenatide at 10 μg/kg significantly reduced food intake (P<0.05) but failed to induce kaolin intake. In general, locomotor activity was reduced at doses of exenatide that decreased food intake, although a slightly higher dose was required to produce significant changes in activity.Conclusion:Systemic exenatide reduces body weight gain in normal, high-fat-fed rodents, a model that parallels human genetic variation and food consumption patterns, and may play a role in metabolic pathways mediating food intake.

KW - Body composition

KW - High fat diet

KW - Kaolin consumption

KW - Locomotor activity

KW - Metabolites

KW - Type 2 diabetes

UR - http://www.scopus.com/inward/record.url?scp=33748118597&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33748118597&partnerID=8YFLogxK

U2 - 10.1038/sj.ijo.0803284

DO - 10.1038/sj.ijo.0803284

M3 - Article

C2 - 16534527

AN - SCOPUS:33748118597

VL - 30

SP - 1332

EP - 1340

JO - International Journal of Obesity

JF - International Journal of Obesity

SN - 0307-0565

IS - 9

ER -